Addition of rituximab to standard chemotherapy does not influence response rates in older ...

December 07, 2003

(San Diego, Calif., December 7, 2003) - Adding rituximab to the standard chemotherapy regimen for lymphoma patients, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), does not significantly increase survival in older patients with diffuse large B-cell lymphoma, according to a study presented today during the 45th Annual Meeting of the American Society of Hematology (ASH). Rituximab is a monoclonal antibody used to treat certain lymphomas that have lymphocytes with the CD20 receptor.

The research team, headed by Thomas Habermann, M.D., of the Eastern Cooperative Oncology Group, Boston, Mass., concluded that the addition of rituximab to the CHOP regimen as a first-line treatment did not influence overall response rates or early progression in patients.

Overall response rates achieved were 77 percent with R-CHOP versus 76 percent with CHOP alone. Progressive disease during treatment occurred in 6.5 percent of patients on R-CHOP versus 10.5 percent on CHOP alone. With a median follow-up of 2.7 years, the time-to-treatment failure (TTF) favored R-CHOP for induction, but there was no difference in overall survival.

Researchers randomized 632 patients with diffuse large B-cell lymphoma (DLBCL), median age 69 years, to either R-CHOP (318 patients) [administered as cyclophosphamide 750 mg/m2 IV day 1; doxorubicin 50 mg/m2 IV day 1; vincristine 1.4 mg/m2 (maximum dose=2) day 1; prednisone 100 mg/m2 days one to five; rituximab 375 mg/m2 day seven, three and two days before cycles three, five, and seven] or CHOP (314 patients) [two cycles beyond complete remission (total six to eight cycles)]. Researchers further randomized patients who achieved either complete or partial response to maintenance rituximab (207 patients; 375 mg/m2 weekly for four weeks repeated every six months times four) versus observation (208 patients). Patients who were included in the results were 540 for induction (initial) therapy and 348 for maintenance.

At six months, and prior to the second randomization, the TTF failure rates were 15 percent for R-CHOP and 17 percent for CHOP. TTF also favored maintenance rituximab, but there was no difference in overall survival. For patients treated with R-CHOP, there was no significant difference seen in maintenance rituximab versus observation in either TTF or overall survival. Conversely, CHOP patients had a significantly longer TTP with maintenance rituximab but no statistically significant prolongation in overall survival.

"Nearly half of patients with diffuse large B-cell lymphoma can be successfully treated with therapy," said Ronald Hoffman, M.D., President of the American Society of Hematology. "Therefore, it is important to identify whether the addition of new treatments, such as rituximab, to the current standard regimen has added benefit. It is the goal of hematologists to treat our patients with the best available treatments, with the least amount of drugs necessary."

Approximately 31 percent of all lymphomas are diffuse large B-cell lymphoma (DLBCL), according to the American Cancer Society. DLBCL is a fast growing lymphoma, whose usual symptoms are a quickly growing mass in the body or in a lymph node that patients can feel. Although it usually starts in lymph nodes, DLBCL can grow in other areas, such as the bones, the brain, or the spinal cord. About one-third of these lymphomas are confined to one part of the body. When it is confined, DLBCL is considered to be more curable than when it has spread to other parts of the body. DLBCL can affect any age group but occurs mostly in older people, with an average age in the mid-60s. Approximately 50 percent of people with this lymphoma are cured with therapy.
The American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

American Society of Hematology

Related Lymphoma Articles from Brightsurf:

Oncotarget: An integrative microenvironment approach for follicular lymphoma
Oncotarget Volume 11, Issue 33 features Figure 8, ''Haplotype estimates in follicular lymphoma patients,'' by Assis-Mendonça, et al. which reported that the authors tested associations between SNPs, clinicopathological features and TME composition, and proposed survival models in R-CHOP/R-CVP-treated patients.

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine.

Lymphoma's different route revealed
Researchers at the MDC observe the very early stages of blood vessel development in lymph node tumors.

Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma
Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-Cell Receptor Signaling.

Suspect eliminated as a therapeutic target in B cell lymphoma
Australian researchers have narrowed the focus on which survival proteins are important for the survival of B cell lymphomas, eliminating the protein BCL-W from the 'suspect list'.

New factor in the development of childhood lymphoma
The immune system is highly complex and a detailed understanding of many underlying mechanisms is still lacking.

Antibiotics can inhibit skin lymphoma
New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma.

Association of BRCA2 mutations with risk of childhood lymphoma
This research letter reports on the association of BRCA2 gene mutations and potential risk for pediatric or adolescent lymphoma.

Why Hodgkin's lymphoma cells grow uncontrollably
Although classical Hodgkin's lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery.

Read More: Lymphoma News and Lymphoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to